Bristol Myers to buy RayzeBio for about $4.1 billion
Bristol Myers Squibb announced that it will buy RayzeBio for about $4.1 billion to bolster its cancer drug business, the second major deal the drugmaker has struck in less than a week.
POPULAR POSTS
Trump opts for personal ties to choose his government team
November 15, 2024
UK sets new climate target for 2035
November 13, 2024
Children go back to school after Valencia floods
November 13, 2024
Researchers document huge decline in African elephants
November 13, 2024
LIVE STREAM
